Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: An electronic device has a calibration arrangement for controlling a frequency characteristic of a PLL circuit having a phase comparator having an output for generating a phase difference signal, a voltage controlled oscillator and a divider. The divisor of the divider is programmable, and the oscillator is also directly modulated by an oscillator modulation signal. A modulation unit has a modulation input for receiving a modulation signal and generates the oscillator modulation signal and the divisor such that modulation generates a predefined change of the output frequency and a change of the divisor proportional to said predefined change. The calibration arrangement receives the phase difference signal, and has a ripple detector for providing a detector output signal by detecting a ripple on the phase difference signal correlated to edges in the modulation signal. A calibration control unit adjusts the oscillator modulation signal based on the detector output signal such that the ripple is reduced.

Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, to a method of selecting an appropriate chemotherapeutic treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and when the expression level is determined a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.

Abstract: An antenna diversity system comprises a diversity transmitter having a plurality of transmitter-side antennas, the diversity transmitter being arranged to generate at least one sequence of signals comprising data packets having payloads identical and identifiers different for each of the data packets, each of the identifiers identifying a corresponding one of the plurality of transmitter-side antennas; and to successively transmit at least two of the signals at different points in time on the corresponding ones of the plurality of transmitter-side antennas; and a receiver comprising a first receiver-side antenna, the receiver being arranged to successively receive the signals of the at least one sequence on the first receiver-side antenna, and to suspend receiving of subsequent signals of the at least one sequence when an error check of a data packet comprised in a received signal of the at least one sequence indicates a successful reception.

Abstract: An integrated circuit device comprising at least one radio frequency (RF) transceiver module. The at least one RF transceiver module includes a plurality of low noise amplifiers (LNAs) operably coupled to external contacts of the integrated circuit device and arranged to receive an RF signal from the respective external contact, amplify the received RF signal, and to output the amplified RF signal. Each transceiver module further includes a plurality of power amplifier (PA) modules operably coupled to the external contact of the integrated circuit device, and arranged to receive an RF signal to be transmitted, amplify the received RF signal to be transmitted, and output the amplified signal. The plurality of LNAs and the plurality of PAs are selectively configurable to operate in at least a first, multi-antenna configuration and a second, single antenna high transmit power configuration.

Abstract: The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: The present invention relates to methods for the treatment of disorders mediated by MICA-expressing cells using antibodies, antibody fragments, and derivatives thereof that specifically bind MICA. The invention also relates to antibodies; cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; and pharmaceutical compositions comprising the same.

Abstract: The present application relates to methods for the enzymatic functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract: An electronic device has a calibration arrangement for controlling a frequency characteristic of a PLL circuit having a phase comparator having an output for generating a phase difference signal, a voltage controlled oscillator and a divider. The divisor of the divider is programmable, and the oscillator is also directly modulated by an oscillator modulation signal. A modulation unit has a modulation input for receiving a modulation signal and generates the oscillator modulation signal and the divisor such that modulation generates a predefined change of the output frequency and a change of the divisor proportional to said predefined change. The calibration arrangement receives the phase difference signal, and has a ripple detector for providing a detector output signal by detecting a ripple on the phase difference signal correlated to edges in the modulation signal. A calibration control unit adjusts the oscillator modulation signal based on the detector output signal such that the ripple is reduced.

Abstract: Disclosed herein are anti-TLR3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-TLR3 antibodies.

Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.

Abstract: A diversity receiver comprises a plurality of receiving paths connected to a receiver circuit. Each of the receiving paths comprises an antenna receiving a signal, connected to a matching network connected to a receive amplifier. The receiver circuit is connected to a signal level comparison circuit for providing a relative comparison value indicating one of the receiving paths receiving the signal with a relative maximum strength. The signal level comparison circuit comprises a comparator circuit connected to the receiver circuit receiving a currently received signal level, and to a logic control unit being arranged to select one of the receive paths to provide the currently received signal to the receiver circuit.

Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.

Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.

Abstract: The detector comprises a plurality of detection stages connected to a summator for providing a summation signal as a logarithmic representation of the input signal to a first input of a data slicer and an input of an average filter having an output connected to a second input of the data slicer. The data slicer has a data slicer output for providing an extracted digital data signal in dependence on a comparison of the summation signal and an output signal of the average filter. The average filter receives a first pre-charge voltage and a second pre-charge voltage depending on an output signal of a carrier detector circuit detecting a carrier signal of the input signal.

Abstract: A process for preparing an at least partially lithiated transition metal oxyanion-based lithium-ion reversible electrode material, which includes providing a precursor of said lithium-ion reversible electrode material, heating said precursor, melting same at a temperature sufficient to produce a melt including an oxyanion containing liquid phase, cooling said melt under conditions to induce solidification thereof and obtain a solid electrode that is capable of reversible lithium ion deinsertion/insertion cycles for use in a lithium battery. Also, lithiated or partially lithiated oxyanion-based-lithium-ion reversible electrode materials obtained by the aforesaid process.

Abstract: The present invention relates to antibodies, antibody fragments, and derivatives thereof that specifically bind to TLR3 cell receptors present on the surface of cells. The invention also relates to hybridomas producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to detect TLR3 levels on the surface of cells, and the use of such antibodies and compositions for diagnostic or therapeutic purposes in subjects.